BRAZIL Trends and Developments Contributed by: Marianne Albers, Thais Fernandes and Mariana Vianna, Felsberg Advogados
Felsberg Advogados Rua Lemos Monteiro, 120–19º andar São Paulo – SP 05501-050 Brazil Tel: +5511 3141 9100 Email: info@felsberg.com.br Web: www.felsberg.com.br/en/
Introduction The Brazilian life sciences market has experi- enced significant growth in recent years, driven by both domestic factors and global trends. With a robust pharmaceutical sector, expanding mar- kets for dietary supplements and cosmetics, and growing interest in innovative healthcare solu- tions, Brazil is emerging as a key player in the global life sciences industry. This text explores the current market trends shaping the sector, including regulatory and legislative changes, technological advancements, and the increasing private collaboration that is fostering investment and growth. It highlights the key sectors, such as pharmaceuticals, cannabis, clinical trials and public-private partnerships, that are poised to drive future development and innovation in Bra- zil’s healthcare landscape in the coming years. Market Trends The Brazilian pharmaceutical sector reached a significant milestone in 2023, following a peri- od of consistent growth in the previous years. Despite global economic challenges, the market posted a solid revenue of USD68 billion, reflect- ing a nominal growth of 8.53% from 2022. Bra- zil remains the largest pharmaceutical market in Latin America, with a 50.7% market share, fol- lowed by Mexico (20.7%) and Argentina (10.4%).
Together, these three countries account for 82% of the region’s total market. In Brazil, the sector has benefited from a sub- stantial increase in public health spending, par- ticularly in 2022–2023, compared to the pre- pandemic period. According to market insights , this surge has been supported by a rapidly expanding private healthcare segment, which is tapping into new markets like pet insurance and embracing digital channels in wholesale. In addition, the Brazilian Federal Government legal framework and new regulation promises numerous investments in the health sector, with high expectations for the effective increase of partnerships between state-owned companies and national and/or foreign companies aiming for a bigger development and innovation in the health sector, especially in the field of pharma- ceuticals. In light of recent global trade dynamics, the Bra- zilian pharmaceutical market is poised to become an increasingly attractive destination for foreign companies. The US imposition of 25% tariffs on imports from Canada and Mexico, along with a 10% tariff on Chinese imports – one of the main markets of API – is expected to create new chal- lenges for the pharmaceutical industry in North
59
CHAMBERS.COM
Powered by FlippingBook